Targeting resistance mechanisms in advanced prostate cancer
Official title: "DNMT and TET1 reprogramming as a targetable mechanism of resistance in advanced prostate cancer"
Funded at Weill Medical Coll of Cornell Univ · NIH-11094021 · Data updated 2026-11-12
This study is looking at how advanced prostate cancer can change into a tougher form called neuroendocrine prostate cancer, and it's trying to find new ways to treat it to help patients feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | June 1, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $645,518 |
| NIH project number | 5R01CA274963-03 |
| Project ID | NIH-11094021 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with advanced prostate cancer, especially those who have developed neuroendocrine features or have shown resistance to androgen-targeting therapies.
✕Less likely to help
Patients with early-stage prostate cancer or those who have not yet undergone treatment may not benefit from this research.
What this research studies
This research investigates how advanced prostate cancer can transform from a hormone-sensitive form to a more aggressive, hormone-resistant type known as neuroendocrine prostate cancer (NEPC). The study focuses on understanding the molecular and epigenetic changes that occur during this transformation, which could lead to new treatment strategies. By using patient-derived organoids and genetically engineered mouse models, researchers aim to identify potential therapeutic targets that could improve outcomes for patients with NEPC. The goal is to develop effective treatments for this challenging and aggressive form of prostate cancer.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively treat advanced prostate cancer, particularly in patients whose cancer has become resistant to standard hormone therapies.
How similar studies have gone: Previous research has shown promise in targeting epigenetic changes in cancer, suggesting that this approach could be effective, although the specific focus on NEPC is relatively novel.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Rickman, David S. — Weill Medical Coll of Cornell Univ
- Study coordinator: Rickman, David S.
Related research
Other NIH-funded projects on the same topics.
-
Drug that blocks tumor-made male hormones and the androgen receptor for advanced prostate cancer
A new medicine aims to block both the androgen receptor and the tumor’s own production of male hormones to help men with advanced, treatment‑resistant prostate cancer.
-
Boosting a tumor-suppressing enzyme to fight advanced prostate cancer
A research grant aims to develop new molecules that enhance the PP2A enzyme to slow or stop progression of advanced prostate cancer.
-
Modulating Androgen Signals to Boost CAR T Therapy for Prostate Cancer
A new approach uses CAR T cells targeting STEAP1 to treat advanced prostate cancer, with a focus on how androgen signals affect treatment effectiveness.
-
Genomic clues to guide therapy in advanced prostate cancer
This grant looks at how a patient’s tumor and germline DNA could predict which targeted or immune therapies will work best for advanced prostate cancer.
-
DACH1-based test to predict therapy response in advanced prostate cancer
A new test using DACH1 and other markers on prostate cancer tissue aims to predict which patients will respond to therapy and guide clinical trials.
-
Understanding how doctors choose treatments to improve advanced prostate cancer care
A clinician-researcher at Duke is exploring how medical decisions are made in advanced prostate cancer to help patients get better, fairer care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.